Biological and Pharmaceutical Bulletin
The Pharmaceutical Society of Japan, established in 1880, is one of Japan’s oldest and most distinguished academic societies. The Society currently has around 18,000 members. It publishes three monthly scientific journals. Chemical and Pharmaceutical Bulletin (Chem. Pharm. Bull.) began publication in 1953 as Pharmaceutical Bulletin. It covers chemistry fields in the pharmaceutical and health sciences. Biological and Pharmaceutical Bulletin (Biol. Pharm. Bull.) began publication in 1978 as the Journal of Pharmacobio-Dynamics. It covers various biological topics in the pharmaceutical and health sciences. A fourth Society journal, the Journal of Health Science, was merged with Biol. Pharm. Bull. in 2012. Yakugaku Zasshi (Japanese for “Pharmaceutical Science Journal”) has the longest history, with publication beginning in 1881. Yakugaku Zasshi is published mostly in Japanese, except for some articles related to clinical pharmacy and pharmaceutical education, which are published in English.
The main aim of the Society’s journals is to advance the pharmaceutical sciences with research reports, information exchange, and high-quality discussion. The average review time for articles submitted to the journals is around one month for first decision. The complete texts of all of the Society’s journals can be freely accessed through J-STAGE. The Society’s editorial committee hopes that the content of its journals will be useful to your research, and also invites you to submit your own work to the journals.

Chairman of Committee
Ken-ichi Hosoya
Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama



Read more
Published by The Pharmaceutical Society of Japan  
9,640 registered articles
(updated on November 21, 2018)
Online ISSN : 1347-5215
Print ISSN : 0918-6158
1.694
2017 IMPACT FACTOR
JOURNALS PEER REVIEWED FREE ACCESS FULL-TEXT HTML ADVANCE PUBLICATION
Featured article
Volume 41 (2018) Issue 11 Pages 1716-1721
Analysis of Glycoforms and Amino Acids in Infliximab and a Biosimilar Product Using New Method with LC/TOF-MS
Masahiro Tsuda, Yuki Otani, Atsushi Yonezawa, Sho Masui, Yasuaki Ikemi, Masaya Denda, Yuki Sato, Shunsaku Nakagawa, Tomohiro Omura, Satoshi Imai, Takayuki Nakagawa, Makoto Hayakari, Kazuo Matsubara

Biosimilar products of therapeutic antibodies have been launched all over the world. They can relieve some of the economic burden of medicines. Although clinical trials have demonstrated the equivalency of biosimilar products with their reference product, biosimilar products are not commonly used in clinical practice. One reason is that the structural difference between the reference product and a biosimilar one remains unclear. We analyzed glycoforms and amino acids of an infliximab biosimilar product approved in Japan compared to that of the reference product (Remicade®). By combination of papain digestion and LC/ time-of-flight (TOF)-MS, we established a valuable method to analyze these therapeutic antibodies. Nine glycoforms were detected in infliximab, and a difference in amino acids was observed. In the glycoforms of MMF, MGnF/GnMF, GnGn, GnGnF, AGnF/GnAF, and AAF, the relative intensities were significantly different between the reference and biosimilar product. Furthermore, we elucidated that the content rate of the C-terminal lysine was different among glycoforms. In conclusion, our analytical method can analyze not only amino acids but also carbohydrate chains of therapeutic antibodies, and will provide a useful strategy to evaluate bio-medicines including biosimilar antibodies.
Read more
Editor’s picks

How can you know the structural difference between biosimilar and reference product? The structure of biosimilar products is not the same as their original product because of post-translational modifications. In the article by Tsuda et al., a valuable method with a papain digestion and LC/TOF-MS analysis was established. Their new method can analyze not only carbohydrate chains but also amino acids of bio-medicines including biosimilar antibodies. This technology will provide a useful strategy to evaluate bio-medicines including biosimilar antibodies.




View the past featured articles
Most viewed articles Oct.2018
Share this page
Select past volume & issue
Favorites & Alerts
Journal news & Announcements
  • Biol. Pharm. Bull. Vol. 41 No. 10
    Current Topics: Transporter Research Yields New Discoveries in Life Sciences
  • Biol. Pharm. Bull. Vol. 41 No. 9
    Current Topics: Recent Advances in Research on Biological Membranes That Regulate the Central Nervous System




  • Biol. Pharm. Bull. Vol. 41 No. 8
    Current Topics: Ion Channels as Therapeutic Targets for the Immune, Inflammatory, and Metabolic Disorders




  • Biol. Pharm. Bull. Vol. 41 No. 7
    Current Topics:New Insights into Neurozinc and Metallothioneins




  • Biol. Pharm. Bull. Vol. 41 No. 3
    Current Topics: Cutting-Edge Studies Using Artificial Membranes
Predecessor

The annual reports of the Public Health Division of the Pharmaceutical Society of Japan

Eisei kagaku

Journal of Health Science

Journal of Pharmacobio-Dynamics

feedback
 Top